For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to…
Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Since 2012,…
Myasthenia gravis (MG) is a rare neuromuscular disorder commonly caused by autoantibodies targeting acetylcholine (ACh) receptors and therefore affecting neuromuscular synaptic transmission at the…
In the last decades, markedly improved survival benefit has been achieved in the treatment of advanced or metastatic HER2-positive breast cancer. Effective HER2-targeted drugs such as Herceptin,…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and understanding of the disease’s pathophysiology has improved…
Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well established, with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta blockers…
The treatment landscape for coronavirus disease 2019 (COVID-19) continues to evolve rapidly. Despite the availability of vaccines in the markets under study, research is ongoing to lower viral…
More than 30 million people in the United States are afflicted with osteoarthritic (OA) pain; we expect an aging population and the increasing prevalence of obesity to drive further growth…